| Enshuxing (enlonstobart) / CSPC Pharma, Sumgen Biotech |
NCT05068141: A Study to Evaluate the Efficacy and Safety of SG001 in Combination With Nab-Paclitaxel in Patients With Advanced Triple-Negative Breast Cancer (TNBC) |
|
|
| Recruiting | 2 | 79 | RoW | SG001, Nab-paclitaxel | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Triple Negative Breast Cancer | 10/22 | 10/23 | | |
NCT04886700: Study of the SG001 Injection for Patients With Relapsed or Metastatic Uterine Cervical Cancer |
|
|
| Recruiting | 2 | 104 | RoW | SG001, Recombinant Human Anti-PD-1 Monoclonal Antibody | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Uterine Cervical Cancer | 12/22 | 12/23 | | |
NCT04983550: Efficacy and Safety of SG001 Combined With PLD in Patients With Platinum-resistant Relapsed EOC |
|
|
| Not yet recruiting | 2 | 126 | NA | SG001, Recombinant Anti-PD-1 Fully Human Monoclonal Antibody Injection, Doxorubicin hydrochloride liposome injection, PLD | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Epithelial Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer | 01/23 | 01/24 | | |
NCT05009953: Study of Irinotecan Liposome Injection in Patients With Advanced Biliary Tract Cancer |
|
|
| Not yet recruiting | 2 | 66 | RoW | Irinotecan Liposome Injection, SG001, Fluorouracil, Leucovorin | CSPC Ouyi Pharmaceutical Co., Ltd. | Advanced Biliary Tract Cancer, Intrahepatic Cholangiocarcinoma, Extrahepatic Cholangiocarcinoma, Gallbladder Carcinoma | 08/23 | 08/24 | | |
NCT06136988: A Study of Docetaxel for Injection (Albumin-bound) and SG001 in Combination With Cisplatin and Simultaneous Radiotherapy for Locally Advanced Unresectable Esophageal Squamous Carcinoma. |
|
|
| Not yet recruiting | 1/2 | 129 | RoW | Docetaxel for Injection (Albumin-bound), HB1801, SG001, Recombinant Anti-PD-1 Fully Human Monoclonal Antibody Injection, Cisplatin for injection, Paclitaxel, Simultaneous Radiotherapy | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Locally Advanced Unresectable Esophageal Squamous Carcinoma | 04/27 | 04/28 | | |
NCT05508659: A Study of Duvelisib Combined With SG001 Injection in Patient With Advanced Solid Tumors |
|
|
| Not yet recruiting | 1/2 | 128 | NA | Duvelisib, COPIKTRA, SG001, Recombinant Anti-PD-1 Fully Human Monoclonal Antibody Injection | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Advanced Solid Tumors | 09/24 | 03/25 | | |
